Nasdaq · CIK 0001727196
SRRK Scholar Rock Holding Corp
Insider trading from SEC Form 4. Last filing 17 d ago. Close $42.19 on Oct 9, 2026, +51% from the 52-week low and -30% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
11
with a Form 4 at this company
Price and insider trades, last year
SRRKOct 9, 2026 · close 42.19
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Scholar Rock Holding Corp, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 33Weak | Jeffrey S. Flier director sell | $1.0M 31,452 shares | -71% | +371% from low-29% from high | |
| 36Weak | Junlin Ho GENERAL COUNSEL sell | $238k 7,442 shares | -3% | +354% from low-31% from high | |
| 32Weak | Richard Brudnick director sell | $181k 6,075 shares | -29% | +322% from low-36% from high | |
| 26Weak | Kristina Burow director sell | $161k 5,400 shares | -20% | +322% from low-36% from high | |
| 27Weak | Jeffrey S. Flier director sell | $181k 6,075 shares | -20% | +322% from low-36% from high | |
| 20Weak | Michael Gilman director sell | $100k 3,375 shares | -6% | +322% from low-36% from high | |
| 53Moderate | Jay T. Backstrom CHIEF EXECUTIVE OFFICER sell | $677k 18,372 shares | -6% | - | |
| 35Weak | Junlin Ho GENERAL COUNSEL sell | $211k 5,742 shares | -3% | - | |
| 58Moderate | Jay T. Backstrom CHIEF EXECUTIVE OFFICER sell | $986k 22,308 shares | -6% | - | |
| 39Weak | Junlin Ho GENERAL COUNSEL sell | $399k 9,039 shares | -4% | - | |
| 42Moderate | Invus Public Equities, L.P. owner sell | $67M 1,600,000 shares | -15% | - | |
| 45Moderate | Invus Public Equities, L.P. owner sell | $16M 409,433 shares | -4% | - | |
| 7Weak | Jing L. Marantz CHIEF MEDICAL OFFICER sell | $316k 8,520 shares | -11% | - | |
| 0Weak | Jing L. Marantz CHIEF MEDICAL OFFICER sell | $63k 2,105 shares | -3% | - |
Transactions
The last 59 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 24, 2026 | Keith Woods Chief Operating Officer | GGift Common Stock | -48,034 | $0.00 | $0 | 572,021 | 17 d ago |
| Sep 21, 2026 | David Hallal Chief Executive Officer | GGift Common Stock | -36,652 | $0.00 | $0 | 1,602,382 | 19 d ago |
| Jun 23, 2025 | Jeffrey S. Flier director | MOption exercise Common Stock10b5-1 | +20,316 | $21.62 | $439k | 44,386 | Jun 25, 2025 |
| Jun 23, 2025 | Jeffrey S. Flier director | SOpen-market sale Common Stock10b5-1 | -17,550 | $32.16 | $564k | 26,836 | Jun 25, 2025 |
| Jun 23, 2025 | Jeffrey S. Flier director | SOpen-market sale Common Stock10b5-1 | -2,766 | $32.74 | $91k | 24,070 | Jun 25, 2025 |
| Jun 23, 2025 | Jeffrey S. Flier director | SOpen-market sale Common Stockindirect: By trust10b5-1 | -11,136 | $33.21 | $370k | 11,136 | Jun 25, 2025 |
| Jun 23, 2025 | Jeffrey S. Flier director | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -20,316 | $0.00 | $0 | 0 | Jun 25, 2025 |
| Jun 16, 2025 | Junlin Ho GENERAL COUNSEL | SOpen-market sale Common Stock | -7,442 | $32.00 | $238k | 222,569 | Jun 17, 2025 |
| Jun 9, 2025 | Junlin Ho GENERAL COUNSEL | AGrant or award Common Stock | +8,571 | $0.00 | $0 | 230,011 | Jun 11, 2025 |
| Jun 9, 2025 | Junlin Ho GENERAL COUNSEL | AGrant or award Stock Option (Right to Buy)derivative | +11,429 | $0.00 | $0 | 11,429 | Jun 11, 2025 |
| May 29, 2025 | Michael Gilman director | SOpen-market sale Common Stock10b5-1 | -630 | $29.22 | $18k | 57,961 | May 30, 2025 |
| May 29, 2025 | Jeffrey S. Flier director | SOpen-market sale Common Stock10b5-1 | -1,100 | $29.23 | $32k | 29,045 | May 30, 2025 |
| May 29, 2025 | Richard Brudnick director | SOpen-market sale Common Stock10b5-1 | -4,675 | $29.63 | $139k | 16,457 | May 30, 2025 |
| May 29, 2025 | Kristina Burow director | SOpen-market sale Common Stock10b5-1 | -1,000 | $29.24 | $29k | 25,471 | May 30, 2025 |
| May 29, 2025 | Kristina Burow director | SOpen-market sale Common Stock10b5-1 | -4,400 | $29.83 | $131k | 21,071 | May 30, 2025 |
| May 29, 2025 | Richard Brudnick director | SOpen-market sale Common Stock10b5-1 | -1,400 | $30.00 | $42k | 15,057 | May 30, 2025 |
| May 29, 2025 | Jeffrey S. Flier director | SOpen-market sale Common Stock10b5-1 | -4,975 | $29.84 | $148k | 24,070 | May 30, 2025 |
| May 29, 2025 | Michael Gilman director | SOpen-market sale Common Stock10b5-1 | -2,745 | $29.83 | $82k | 55,216 | May 30, 2025 |
| May 22, 2025 | Srinivas Akkaraju director | AGrant or award Common Stock | +7,632 | $0.00 | $0 | 21,132 | May 23, 2025 |
| May 22, 2025 | Richard Brudnick director | AGrant or award Common Stock | +7,632 | $0.00 | $0 | 21,132 | May 23, 2025 |
| May 22, 2025 | Kristina Burow director | AGrant or award Common Stock | +7,632 | $0.00 | $0 | 26,471 | May 23, 2025 |
| May 22, 2025 | Michael Gilman director | AGrant or award Common Stock | +7,632 | $0.00 | $0 | 58,591 | May 23, 2025 |
| May 22, 2025 | Jeffrey S. Flier director | AGrant or award Common Stock | +7,632 | $0.00 | $0 | 30,145 | May 23, 2025 |
| May 22, 2025 | Richard Brudnick director | AGrant or award Stock Option (Right to Buy)derivative | +9,206 | $0.00 | $0 | 9,206 | May 23, 2025 |
| May 22, 2025 | Michael Gilman director | AGrant or award Stock Option (Right to Buy)derivative | +9,206 | $0.00 | $0 | 9,206 | May 23, 2025 |
| May 22, 2025 | Jeffrey S. Flier director | AGrant or award Stock Option (Right to Buy)derivative | +9,206 | $0.00 | $0 | 9,206 | May 23, 2025 |
| May 22, 2025 | Kristina Burow director | AGrant or award Stock Option (Right to Buy)derivative | +9,206 | $0.00 | $0 | 9,206 | May 23, 2025 |
| May 22, 2025 | Srinivas Akkaraju director | AGrant or award Stock Option (Right to Buy)derivative | +9,206 | $0.00 | $0 | 9,206 | May 23, 2025 |
| May 2, 2025 | David Hallal Chief Executive Officer | AGrant or award Stock Option (Right to Buy)derivative | +275,167 | $0.00 | $0 | 275,167 | May 6, 2025 |
| Apr 27, 2025 | David Hallal CEO | AGrant or award Common Stock | +250,000 | $0.00 | $0 | 554,095 | Apr 29, 2025 |
| Apr 27, 2025 | David Hallal CEO | AGrant or award Common Stock | +1,250,000 | $0.00 | $0 | 1,804,095 | Apr 29, 2025 |
| Mar 10, 2025 | Jay T. Backstrom CHIEF EXECUTIVE OFFICER | AGrant or award Common Stock | +113,570 | $0.00 | $0 | 425,561 | Mar 12, 2025 |
| Mar 10, 2025 | Junlin Ho GENERAL COUNSEL | AGrant or award Common Stock | +32,145 | $0.00 | $0 | 221,440 | Mar 12, 2025 |
| Mar 10, 2025 | Jay T. Backstrom CHIEF EXECUTIVE OFFICER | AGrant or award Stock Option (Right to Buy)derivative | +151,430 | $0.00 | $0 | 151,430 | Mar 12, 2025 |
| Mar 10, 2025 | Junlin Ho GENERAL COUNSEL | AGrant or award Stock Option (Right to Buy)derivative | +42,855 | $0.00 | $0 | 42,855 | Mar 12, 2025 |
| Feb 18, 2025 | Jay T. Backstrom CHIEF EXECUTIVE OFFICER | SOpen-market sale Common Stock | -18,372 | $36.83 | $677k | 311,991 | Feb 20, 2025 |
| Feb 18, 2025 | Junlin Ho GENERAL COUNSEL | SOpen-market sale Common Stock | -5,742 | $36.83 | $211k | 189,295 | Feb 20, 2025 |
| Jan 16, 2025 | Jay T. Backstrom CHIEF EXECUTIVE OFFICER | SOpen-market sale Common Stock | -22,308 | $44.20 | $986k | 330,363 | Jan 21, 2025 |
| Jan 16, 2025 | Junlin Ho GENERAL COUNSEL | SOpen-market sale Common Stock | -9,039 | $44.20 | $399k | 195,037 | Jan 21, 2025 |
| Dec 10, 2024 | Invus Public Equities, L.P. owner | SOpen-market sale Common Stock | -1,600,000 | $41.65 | $67M | 9,250,005 | Dec 12, 2024 |
| Nov 25, 2024 | Invus Public Equities, L.P. owner | SOpen-market sale Common Stock | -208,272 | $37.63 | $7.8M | 11,051,166 | Nov 27, 2024 |
| Nov 25, 2024 | Invus Public Equities, L.P. owner | SOpen-market sale Common Stock | -43,887 | $38.43 | $1.7M | 11,007,279 | Nov 27, 2024 |
| Nov 25, 2024 | Invus Public Equities, L.P. owner | SOpen-market sale Common Stock | -126,442 | $39.51 | $5.0M | 10,880,837 | Nov 27, 2024 |
| Nov 25, 2024 | Invus Public Equities, L.P. owner | SOpen-market sale Common Stock | -30,683 | $40.14 | $1.2M | 10,850,154 | Nov 27, 2024 |
| Nov 25, 2024 | Invus Public Equities, L.P. owner | SOpen-market sale Common Stock | -149 | $40.98 | $6,106 | 10,850,005 | Nov 27, 2024 |
| Nov 22, 2024 | Jing L. Marantz CHIEF MEDICAL OFFICER | MOption exercise Common Stock10b5-1 | +2,145 | $8.59 | $18k | 75,000 | Nov 26, 2024 |
| Nov 22, 2024 | Jing L. Marantz CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock10b5-1 | -2,145 | $30.01 | $64k | 72,855 | Nov 26, 2024 |
| Nov 25, 2024 | Jing L. Marantz CHIEF MEDICAL OFFICER | MOption exercise Common Stock10b5-1 | +6,375 | $8.59 | $55k | 79,230 | Nov 26, 2024 |
| Nov 25, 2024 | Jing L. Marantz CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock10b5-1 | -1,000 | $38.04 | $38k | 78,230 | Nov 26, 2024 |
| Nov 25, 2024 | Jing L. Marantz CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock10b5-1 | -2,100 | $39.25 | $82k | 76,130 | Nov 26, 2024 |
| Nov 25, 2024 | Jing L. Marantz CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock10b5-1 | -3,075 | $39.93 | $123k | 73,055 | Nov 26, 2024 |
| Nov 25, 2024 | Jing L. Marantz CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock10b5-1 | -200 | $40.72 | $8,144 | 72,855 | Nov 26, 2024 |
| Nov 22, 2024 | Jing L. Marantz CHIEF MEDICAL OFFICER | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -2,145 | $0.00 | $0 | 136,375 | Nov 26, 2024 |
| Nov 25, 2024 | Jing L. Marantz CHIEF MEDICAL OFFICER | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -6,375 | $0.00 | $0 | 130,000 | Nov 26, 2024 |
| Nov 12, 2024 | Michael Gilman director | GGift Common Stockindirect: By trust | -37,459 | - | - | 0 | Nov 13, 2024 |
| Nov 11, 2024 | Jing L. Marantz CHIEF MEDICAL OFFICER | MOption exercise Common Stock10b5-1 | +2,105 | $8.59 | $18k | 74,960 | Nov 13, 2024 |
| Nov 12, 2024 | Michael Gilman director | GGift Common Stock | +37,459 | - | - | 50,959 | Nov 13, 2024 |
| Nov 11, 2024 | Jing L. Marantz CHIEF MEDICAL OFFICER | SOpen-market sale Common Stock10b5-1 | -2,105 | $30.00 | $63k | 72,855 | Nov 13, 2024 |
| Nov 11, 2024 | Jing L. Marantz CHIEF MEDICAL OFFICER | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -2,105 | $0.00 | $0 | 138,520 | Nov 13, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Srinivas Akkarajuowner, director
- Jay T. BackstromCHIEF EXECUTIVE OFFICER
- Richard Brudnickofficer, director
- Kristina Burowdirector, owner
- Jeffrey S. Flierdirector
- Michael Gilmandirector
- David HallalChief Executive Officer
- Junlin HoGENERAL COUNSEL
- Invus Public Equities, L.P.owner
- Jing L. MarantzCHIEF MEDICAL OFFICER
- Keith WoodsChief Operating Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.